SLAMF7
SLAM family member 7
As of the edition of 20 October 2026, SLAMF7 (SLAM family member 7, UniProt Q9NQ25) has 2 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NQ25
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Cancer; Immune system; Blood and lymph; Heart and blood vessels; Nutrition and metabolism
- Registered trials of its drugs
- 62
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Elotuzumab | Marketed | Phase 3 | Ends 2027 |
| Azintuxizumab vedotin | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| AbbVie | Route A |
The other 2 companies at SLAMF7
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at SLAMF7, ranked, with the facts behind eachRequest access. Nothing is shown until you do.